RxDoctor Payments DataLook up a doctor →

Cezar Staniloae, MD

Cardiovascular Disease · New York, NYNPI 1336112150

Payments from drug & device makers

$1,178,739in general payments, 2019–2025

Across 526 payments — averaging $2240.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$291K
  • Novartis$284K
  • Edwards Lifesciences$248K
  • Medtronic$151K
  • Boehringer Ingelheim International GmbH$38K
  • Abbott$36K
  • plus $131K from 10 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,178,739 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$230,785
Medicare patients
296
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →